Evidence map›Paper›PMID 40323647›Full record

SynthesisJournal of medical Internet research2025

The Application Status of Radiomics-Based Machine Learning in Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-Analysis.

Lan Xu, Zian Chen, Dan Zhu, Yingjun Wang

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lan XuDepartment of First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0000-0003-1419-4654
Zian ChenDepartment of First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.ORCID https://orcid.org/0009-0000-3814-1595
Dan ZhuDispensary TCM, Quzhou Municipal Hospital of Traditional Chinese Medicine, Quzhou, China.ORCID https://orcid.org/0009-0007-5255-3044
Yingjun WangDepartment of Dermatology, Quzhou Municipal Hospital of Traditional Chinese Medicine, Quzhou, China.ORCID https://orcid.org/0009-0003-5699-4569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the past few years, radiomics for the detection of intrahepatic cholangiocarcinoma (ICC) has been extensively studied. However, systematic evidence is lacking in the use of radiomics in this domain, which hinders its further development.

objectiveTo address this gap, our study delved into the status quo and application value of radiomics in ICC and aimed to offer evidence-based support to promote its systematic application in this field.

methodsPubMed, Web of Science, Cochrane Library, and Embase were comprehensively retrieved to determine relevant original studies. The study quality was appraised through the Radiomics Quality Score. In addition, subgroup analyses were undertaken according to datasets (training and validation sets), imaging sources, and model types.

resultsFifty-eight studies encompassing 12,903 patients were eligible, with an average Radiomics Quality Score of 9.21. Radiomics-based machine learning (ML) was mainly used to diagnose ICC (n=30), microvascular invasion (n=8), gene mutations (n=5), perineural invasion (PNI; n=2), lymph node (LN) positivity (n=2), and tertiary lymphoid structures (TLSs; n=2), and predict overall survival (n=6) and recurrence (n=9). The C-index, sensitivity (SEN), and specificity (SPC) of the ML model developed using clinical features (CFs) for ICC detection were 0.762 (95% CI 0.728-0.796), 0.72 (95% CI 0.66-0.77), and 0.72 (95% CI 0.66-0.78), respectively, in the validation dataset. In contrast, the C-index, SEN, and SPC of the radiomics-based ML model for detecting ICC were 0.853 (95% CI 0.824-0.882), 0.80 (95% CI 0.73-0.85), and 0.88 (95% CI 0.83-0.92), respectively. The C-index, SEN, and SPC of ML constructed using both radiomics and CFs for diagnosing ICC were 0.912 (95% CI 0.889-0.935), 0.77 (95% CI 0.72-0.81), and 0.90 (95% CI 0.86-0.92). The deep learning-based model that integrated both radiomics and CFs yielded a notably higher C-index of 0.924 (0.863-0.984) in the task of detecting ICC. Additional analyses showed that radiomics demonstrated promising accuracy in predicting overall survival and recurrence, as well as in diagnosing microvascular invasion, gene mutations, PNI, LN positivity, and TLSs.

conclusionsRadiomics-based ML demonstrates excellent accuracy in the clinical diagnosis of ICC. However, studies involving specific tasks, such as diagnosing PNI and TLSs, are still scarce. The limited research on deep learning has hindered both further analysis and the development of subgroup analyses across various models. Furthermore, challenges such as data heterogeneity and interpretability caused by segmentation and imaging parameter variations require further optimization and refinement. Future research should delve into the application of radiomics to enhance its clinical use. Its integration into clinical practice holds great promise for improving decision-making, boosting diagnostic and treatment accuracy, minimizing unnecessary tests, and optimizing health care resource usage.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaMachine LearningHumansRadiomicsbile duct cancerintrahepatic cholangiocarcinomamachine learningmeta-analysisradiomicsystematic review

Identifiers

PMID40323647
PMCPMC12089883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.